The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to Section 130a (8) SGB V for medicinal products with the active ingredient infliximab - in the dosage form powder for the preparation of a concentrate for infusion solution or powder for a concentrate for the preparation of an infusion solution (ATC: L04AB02) within the framework of a so-called "open-house model". Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with §130 a para. 8 SGB V for the active ingredients mentioned under Section B. Interested pharmaceutical companies can request the participation documents and the respective contract from the contact address mentioned under I.1). A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents completely completed and signed.

Conclusion of non-exclusive discount agreements in accordance with § 130a para. 8 SGB V for medicinal products with the active ingredient infliximab - in the dosage form powder for the production of a concentrate for infusion solution or powder for a concentrate for the preparation of an infusion solution (ATC: L04AB02) with the possibility of conclusion at any time within the framework of a so-called "open-house model". A contract will be concluded with each pharmaceutical company that meets the eligibility requirements. There is no exclusivity.

Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The earliest start date of the contract is 01.11.2023, from which the maximum contract term is 24 months. The contract ends on 31.10.2025 regardless of the start of the contract. Should AOK Sachsen-Anhalt put out to tender exclusive contracts for the active ingredients during the term of the contract in accordance with the relevant procurement regulations, the contracts concluded within the scope of this publication will be terminated in accordance with the contractual provisions.

This publication is not a public contract within the meaning of Section 103 GWB or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are due solely to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.